|
|
VELCADE® (bortezomib) for Injection
The Effect of Novel Antimyeloma Agents on Bone Metabolism
Managing Side Effects of Novel Agents
|
|
|
REVLIMID®, a potent immunomodulatory derivative (IMiD) of thalidomide, induces apoptosis in resistant MM cell lines and patient cells and, more importantly, decreases binding of MM cells to bone marrow stromal cells. |
|
|
|
|
VELCADE® is an antineoplastic agent available for intravenous injection (IV) use only. It has been approved by the FDA for the treatment of myeloma. Watch the "Ask the Expert" Videos from ASCO 2004 and Lymphoma Myeloma Conference 2004 on VELCADE® as treatment and in research. |
|
|
|
|
Helpful information about Thalidomide Therapy for patients and caregivers, including clinical trials with THALOMID®. Watch "Ask the Expert" videos from ASCO 2004 and the Lymphoma Myeloma Conference 2004. |
|
|
|
|
A comprehensive guide to new drugs in development for myeloma. |
|
|
|
|
Dexamethasone, an adrenal corticosteroid, is used to treat multiple myeloma. |
|
|
|
|
Radiation is often used for treatment of myeloma bone disease. |
|
|
|
|
XIIth International Myeloma Workshop in Washington, DCEvangelos Terpos, M.D.
General Air Force Hospital
Athens, Greece
|
|
|
|
|
IMF Nurse Leadership Board Member
Deborah Doss, R.N., OCN
Dana Farber Cancer Institute
Boston, MA |
|
|
step 1: get the correct diagnosis
step 3: Initial treatment options
back
print
related articles
hola soy de república dominicana mi mama fue diagnosticada con miolema y tengo poco conocimiento necesito ayuda
You can contact the IMF Hotline at 800-452-2873 M-Th: 9-4 PST Fri: 9-2 PST.